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Abstract
Deficits in Reelin expression and signaling play a pathogenic role in Alzheimer’s
disease (AD). Thus, strategies aimed at correcting Reelin deficits may provide a novel
therapeutic approach to treating AD. The cysteine-rich, whey protein supplement,
Immunocal®, has recently been shown to rescue Reelin expression in a mouse model of
Schizophrenia. Given that Reelin-expressing neurons of the entorhinal cortex region are
a highly vulnerable population of cells that are lost early in AD, we examined the effects
of Immunocal® in the hippocampal-entorhinal cortex formation in a mouse model of AD.
Glutathione levels and Reelin expression in the hippocampal-entorhinal cortex formation
(entorhinal cortex, EC; dentate gyrus, DG; and Cornu Ammonis, CA1/ Cornu Ammonis,
CA3 regions of hippocampus) of 12-month old hAPPSweInd mice were significantly reduced
when compared to non-carrier controls as measured by HPLC, western blot and
immunohistochemistry respectively. These reductions were prevented in hAPPSweInd mice
when treated with Immunocal® from 3 month to 12-month-old. We assessed the transcript
levels of Reelin using in situ hybridization and show a reduction in Reelin transcript levels
in untreated hAPPSweInd mice compared to non-carrier mice; However, Immunocal®
treatment preserved Reelin transcript levels. Elevating Reelin expression through
treatment with Immunocal® significantly reduced the number, size and density of Amyloglo stained amyloid plaques throughout the hippocampal-entorhinal cortex formation. Our
findings demonstrate that Immunocal® rescues Reelin expression in vivo within the
hippocampal-entorhinal cortex formation of 12-month-old transgenic hAPPSweInd mice. This
rescue of Reelin expression was associated with an amelioration of the pathological
amyloid plaque load. To our knowledge, these data provide the first evidence of a
ii

therapeutic agent that is capable of correcting Reelin deficits in the hAPPSweInd mouse
model of AD. Our findings support the testing of Immunocal® as a novel therapeutic agent
for patients suffering from Alzheimer’s disease.
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Chapter One: Introduction
1.01 Aging and neurodegenerative diseases
Aging is a natural progression of bio-molecular decay that occurs due to entropic
events (DiLoreto et al. 2015). This wear and tear originate from cells and eventually
translates as a loss of function into tissues and organs. Cellular in-house repair and
replacement processes maintain homeostasis such that functional molecules are retained.
However, at the cost of reformation some by-products released are often deleterious and
non-specific to target. Thereby its effects emerge at a later stage, creating a large
asymptomatic period. Consequently, a misbalance in degradation of cellular debris and
repair cycle ensues which ultimately results in Age-Related Diseases (ARD). There are
several diseases such as cardiovascular, diabetes, neurological diseases that have a time
dependency onset. Neurodegenerative diseases make a unique study under ARD since
they are elusive in the field of research creating a large rate limiting step towards
therapeutics.
Neurodegenerative diseases are a cohort of disorders that cause loss of structure
and function in the central and peripheral nervous systems. One of the challenging
aspects in this field is drug delivery. This is due to the presence of a blood brain barrier
which acts as a molecular sieve wherein selectivity is based on polarity and size. Another
complexity of these systems are the maintenance of synapses which assist in
transmission of cellular and electrical signaling. Neuronal cells are more susceptible to
aging diseases due to lack of regeneration capability once they are terminally
1

differentiated. Hence, any disruption in synaptic connections that may be the result of
deficits in protein synthesis can lead to neuronal death. In order to address these
challenges, there is a dire need to understand fundamental processes that are involved in
building and maintaining neuronal connections. Alzheimer’s disease is one such disease
that is a representation of neurodegeneration along the aging process. It currently requires
attention due to a growing elderly population that are vulnerable to this form of dementia.
1.02 Prevalence of Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic illness that is clinically characterized by
dementia, behavioral impairment and socio-occupational dysfunction. Dementia is a
syndrome that arises due to number of causes and its phenotypic presentation often
depends on the severity and area of neuronal degradation. Its typical symptoms present
as loss of memory and slow decline of other cognitive functions that affect a person’s
ability to perform daily activities. As the disease progresses, other areas of the brain begin
to degrade that are involved in controlling involuntary activities, making it fatal (Wilson et
al. 2012)
Several statistical studies have estimated that approximately 17% of people in the
USA between the ages of 75-84 years-old have AD. Due to the nature of AD as being a
slow and prolonged debilitating disease, patients often require full attention within
caregiver facilities. This has led to greater costs which are estimated at about 236 billion
dollars per year. It has been projected that the costs will triple by year 2050. According to
the Alzheimer’s Association, approximately 13% of people over age 65 have AD and 45%
of people over the age of 85 have AD. Due to a better healthcare system overall, there is
a larger demographic shift in the population leading to longer lives. Hence it has been
predicted that more people may be susceptible to having AD. Based on this predictive
analysis, about 7.7 million people are projected to have AD and this number is expected
2

to double by 2050. AD is the sixth most common cause of death with over 5 million patients
currently diagnosed in the United States and approximately 500,000 new cases each year
(2017 Alzheimer's disease facts and figures).
1.03 Pathology of Alzheimer’s disease and drug interventions
Alzheimer’s disease was first described in 1906 by Dr. Alois Alzheimer and is
characterized phenotypically by progressive memory loss and cognitive decline (Hanns
Hippius, 2003). Pathological hallmarks of the disease include amyloid plaques consisting
of insoluble deposits of amyloid beta (A) peptide and neurofibrillary tangles containing
hyper-phosphorylated tau protein (Fig 1.) (L.Muche, 2009). These plaques and tangles
are found throughout the brain parenchyma and are believed to play a significant role in
the neuronal loss and atrophy that are characteristic of the AD brain. Of the diverse
neuronal cell types that die in AD, hippocampal pyramidal cells, cortical pyramidal cells,
and basal forebrain cholinergic neurons are among the most severely affected. The death
of these populations of neurons leads to profound synaptic loss and significant
neurotransmitter deficits, particularly in cholinergic pathways (Del Turco, D. et al. 2016)
Although 3 genes (amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2
(PS2)) have been shown to be mutated in early onset, autosomal dominant, familial AD,
these inherited forms of the disease make up less than 5% of AD cases, with the remaining
95% of cases being sporadic in nature (Cacace, R. et al. 2016).
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Figure 1: Cellular events of AD pathology (Figure adapted from L.Muche, 2009)
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Aβ is produced from amyloid precursor protein (APP). They tend to disrupt space between neurons,
synapses hindering cell to cell communication
Fibrils of amyloid-β oligomers form plaques.
Inflammatory response to plaques leads microglial cells to release of cytokines that eventually
lead to neuronal death
Misfolded tau form fibrils inside the neuron that displace intracellular signaling pathways.
Aβ molecule disrupt functions of organelles
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Fig. 2. Distinct pathways of APP proteolytic
processing. APP processing has two different pathways
once it has been inserted into a lipid membrane. The nonamyloidogenic pathway utilizes α-secretase to produce
soluble amyloid-beta precursor protein-alpha (sAPPα) and
C-terminal fragment 83 (CTF83). γ-secretase then cleaves
the CTF83 into a soluble p3 fragment and the amyloid
precursor protein intracellular domain (AICD). The
amyoidogenic pathway utilizes processing by β-secretase,
which produces the soluble amyloid-beta precursor
protein-beta (sAPPβ) and C-terminal fragment 99 or 89
(CTF99/89), depending on tissue type. γ-secretase then
cleaves CTF99/89 into Aβ40 or Aβ42, which become
extracellular, and the AICD. (Figure adapted from Müller
et al. 2008).
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The amyloid cascade hypothesis has dominated the field of AD research for the
past two decades and is founded on the premise that deposition of Aβ peptide is the
initiating event in disease pathogenesis, ultimately leading to neurofibrillary tangle
formation, synaptic loss, and neuronal cell demise (Hardy and Higgins, 1992). For nearly
two decades, the amyloidogenic processing of APP to form Aβ has been recognized as a
viable molecular target for AD therapeutic development (Vassar, 2001; Evin et al. 2006).
The amyloidogenic pathway generates beta amyloid (of which the Aβ1-42 form - here
referred to simply as Aβ) is commonly regarded as the most likely toxic species) through
the sequential cleavage of APP by the beta-site APP cleaving enzyme (BACE; also known
as β -secretase) and γ-secretase. Alternatively, the sequential cleavage of APP by αsecretase and γ - secretase is considered non-amyloidogenic (Fig. 2)
Based largely on the amyloid cascade hypothesis (Fig. 3), selective inhibitors of
BACE and γ -secretase have been developed as drugs to decrease the tissue load of Aβ
in AD brain (Vassar et al., 2009; D’Onofrio et al. 2012). Unfortunately, amyloid altering
drugs have resulted in largely disappointing results in the clinic. For instance, two large
Phase III clinical trials of the γ -secretase inhibitor, semagacestat, in mild-to-moderate AD
5

patients were terminated early due to a statistically significant worsening of clinical
measures of cognition and ability to perform activities associated with daily living
(D’Onofrio et al. 2012). Even more recently, Eli Lilly’s anti-amyloid antibody, solanezumab,
failed in a Phase III trial of patients with mild-to-moderate AD and a second trial in
prodromal AD patients was terminated (Mullard A. 2017). The Merck compound, MK-8931
(verubecestat), is a selective BACE inhibitor that initially completed Phase I testing and
reportedly was capable of reducing cerebral spinal fluid amyloid levels by up to 90% in
rats, monkeys, healthy human volunteers, and AD patients (Menting and Claassen, 2014;
Kennedy M.E. et al. 2016). A Phase II/III clinical trial of this drug (EPOCH) completed
enrollment in early 2016 in a population of patients with mild-to-moderate AD.
Unfortunately, in February of 2017, Merck announced that it was terminating the trial after
an interim analysis suggested little chance of discerning any positive therapeutic benefit
(Mullard A. 2017). This was a significant setback for the AD field. As a result of these
recent clinical disappointments, and due to the observation that brain amyloid load does
not necessarily correlate with the severity of cognitive deficits in AD, some have begun to
question whether the amyloid cascade hypothesis is entirely sufficient to explain the
underlying pathogenesis of late onset, sporadic AD (Karran and De Strooper, 2016;
Swerdlow et al. 2017; Tse and Herrup, 2017). Thus, it is essential to identify novel
therapeutic approaches that are not focused exclusively on reducing amyloid load in the
AD brain.
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Fig 3. An Illustration of amyloid cascade hypothesis. (Figure adapted from Singh et al. 2016)

1.04 Extracellular secreted protein: Reelin
Reelin may be one such novel approach for AD. It is a large secreted glycoprotein
which plays a key role in patterning and layering of the cerebral cortex and other regions
of the brain during development (Niu et al. 2004; Beffertt al. 2006; Kim et al. 2015; Bosch
et al. 2016). Reelin has specific roles in each developmental phase of the central and
peripheral nervous system. This protein was discovered in 1951 as a spontaneous
mutation variant in mice which have a typical neurological phenotype of ataxia and
“reeling” gait that is an inability to move around the cage (Falcon DS, 1951; Lambert de
Rouvroit and Goffinet, 1998). Through chromosome mapping, the reelin gene was found
to be present on chromosome 7q22. Later, antibodies were successfully raised against
reelin which was termed as CR-50 (Cajal-Retzius 50 marker). During prenatal
development Cajal Retzius (CR) are primary cells in the marginal zone that secrete reelin
(D’Arcangelo et al. 1997; Ogawa et al. 1995). Failure to form normal cortical plates in the
cerebrum and cerebellar hypoplasia are distinct pathological characteristics of reeler
mutant mice (Hong et al. 2000). Through this study of histological sections of brain, it was
7

discovered that reelin plays a significant role in neuronal patterning in the predevelopmental period (Gabriella D'Arcangelo et al.1995). To achieve correct architecture
of neocotex, reelin acts as a molecular cue for cells to migrate enabling cells to reach in
their destined target area (Fig 4.). These mutants have a severe anatomic defect where
all of the layers in the forebrain are disrupted. Shortly after neocortex formation, this
population of CR cells die. During the postnatal development phase, residual CR cells are
involved in functions like axonal maturation and dendrite outgrowth which provides
branching patterns in the brain (Niu et al. 2004; Kupferman et al. 2014). However, in the
adult brain only a subset of cells, especially GABAergic interneurons found in cortical,
granular layer and hippocampal regions, secrete reelin, and are thought to be involved in
synaptic plasticity (Pesold et al. 1998). Therefore, Reelin has myriad roles such as those
involved in axonal and dendrite outgrowth, synaptogenesis, spine formation, long term
potentiation in developing and post-development phases (Weeber et al. 2002; Beffert et
al. 2005). This indicates that it acts on heterogenous cell populations such as glial cells,
astrocytes, stem cells, newborn and differentiated cells etc. This spatiotemporal regulation
could be attained through various structural conformations of reelin.

8
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Fig 4. Schematic representation of early cortical development in mice and reelin function in
brain development. A)At embryonic day (E) 13.5 (The preplate stage) neurons colonize maybe
through somal translocation and form a horizontal trail of cells, as directed by arrows. At this stage
reeler phenotype is not distinct from wild type. At E14.5 as embryonic plate complexity increases, cells
migrate along the glial fibers. The cells in fluorescent green condense in cortical plate forming two
distinct compartments, while in reeler phenotype, same cells are obliquely oriented and does not split
the preplate into two compartments. At E15.5, a second group of cells (magenta) migrate through the
cortical plate and settle superficially forming an inside to outside gradient. In reeler mutants, these
newly formed cohort cells settle in deeper layers of cortex forming an outside to inside gradient.
(Adapted from Fadel Tissir 2003)
B)Green squares represent reelin producing cells that are localized in marginal zone (MZ) in
predevelopment phase. Purple ovals represent neurnal cell bodies from cortical forebrain (CZ) that
migrate towards MZ. In postnatal development, reelin is involved in axonal and dendritic maturation
while in adulthood it is involved in maintenance of synaptic plasticity. (Adapted from Gabriella
D'Arcangelo 2014).
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1.05 Structure of Reelin
Different functional modalities are contributed by distinct structural features of
reelin. Human full-length reelin protein is approximately 388 KDa and is composed of eight
repeats (R) (Fig. 5). Each of these repeats surround an epidermal growth factor (EGF) like
motif. The N-terminus of reelin contains a signal peptide which is structurally like an Fspondin domain while the C-terminal region is positively charged (D’Arcangelo et
al.,1997). After secretion, this full-length protein undergoes cleaved by metalloproteases
at two sites to create three fragments: an N-terminal (Nt=N-R2), a central(C=R3-R6), and
a C-terminal (Ct=R6-CTR) fragment (Koie et al. 2014; Sato et al. 2016). How each
fragment or full-length protein is functionally activated and/or regulated is unknown.
Although the C-terminal fragment alone was enough for the activation of downstream
signaling pathways and cortical pattering in brain slices. From all collective biochemical
studies, it seems that fragments of reelin act as regulatory molecules on the full-length
protein. At the same time, these fragments also activate signaling pathways that are
distant from their source of origin (Jossin et al. 2007).
Since its role is fundamental for neuronal processes like synaptic plasticity, its
deficits in reelin expression can lead to severe debilitation of motor or cognitive functions.
Several neuropsychiatric disorders such as schizophrenia, autism and depression are
associated with a deficit in reelin signaling.

10

Figure 5. A schematic illustration of reelin protein and its cleavage fragments. Reelin comprises of Nterminal (Nt) signal peptide, F-spondin-like-domain (SL), eight reelin repeats. Each repeat has two
subdomains A and B which is separated by epidermal growth factor (EGF). The full-length protein is cleaved
at sites shown by an arrow. Figure adapted from Lee (2016).

1.06 Signaling pathway of Reelin
Reelin is secreted into the extracellular space where it interacts with one of two
cell surface receptors on target cells, either the very low-density lipoprotein receptor
(VLDLR) or the apolipoprotein E receptor-2 (ApoER2) (Fig.6). Upon binding its receptor,
Reelin induces tyrosine phosphorylation of the adapter protein, Disabled-1 (DAB1), via the
nonreceptor tyrosine kinases, Src or Fyn. Phosphorylated DAB1 acts as a docking site to
initiate multiple downstream signal transduction cascades such as those involved in cell
survival (PI3K/AKT) and regulation of actin assembly (Cdc42/PAK/cofilin) (Fig. 1; Wasser
and Herz, 2017). The pathway described here represents the canonical Reelin signaling
pathway and is the one most commonly attributed to Reelin’s actions in the central nervous
system. However, alternative Reelin signaling pathways do exist, as well as additional
Reelin receptors (Bock and May, 2016; Lee and D’Arcangelo, 2016).

11

Fig. 6. Canonical Reelin signaling pathway. Reelin binds to one of two cell surface receptors, VLDLR
or ApoER2, and induces tyrosine phosphorylation of the adapter protein, Dab1, via Src family kinase
activity. Phosphory-lated Dab1 acts as a docking site to initiate multiple downstream signaling cascades.
(Figure adapted from Wasser and Herz 2017).

1.07 Non-Canonical receptors of Reelin
Non-canonical pathways refer to Reelin’s interaction with cellular receptors other
than VLDLR and/or ApoE2, that further lead to activation of Dab1 (Bock, H. H., & May, P.
2016). The core function of Reelin was realized through its interaction with LDL receptors
and Fyn-dependent NMDA receptors. NMDA receptors are glutamate receptors that are
essential for synaptic plasticity and memory formation. Therefore, Reelin was one of the
extracellular proteins that partakes in LTP by consolidating neuronal synapses.
Apolioproteins are another class of proteins that interact with LDL receptors. A well-known
apolipoprotein variant, ApoE4 has been implicated in sporadic AD. Since the Reelin and
ApoE signaling pathways share a common link with LDL receptors, it has been postulated
that reelin may be a potential molecule involved in APP processing. It has been shown
that reelin levels decrease in an AD mouse model and in AD patients. A novel interaction
between reelin and APP has been demonstrated through several in vivo and in-vitro
experiments. Overall it was shown that Reelin increases APP receptors on the cell surface
12

and decreases processing of APP into Aβ peptides. This study also postulates that the
interactions of Reelin with APP promotes neurite outgrowth in cultured neurons and
dendrite processing in vivo (Hoe, H. S et al., 2009).
1.8 Anatomy of hippocampus
Hippocampus is the region in brain that is predominantly involved with memory
and learning. It is composed of three primary regions - dentate gyrus, subiculum and
entorhinal cortex (Fig 7.). The dentate gyrus is further subdivided into three parts that are
differentiated based on types of cells that populate each part. The molecular layer is a
cell-free layer and is composed of apical dendrites that branch in from granular cells. The
intermediate layer of DG is also known as the granular layer and consists of a large
population of granule cells. Following this layer is the Hilus layer which is distinctively
composed of mossy cells. The Cornus Ammonis (CA) is the elongated C shaped structure
which is composed of pyramidal cells. This CA region is also sub-divided into three
regions, beginning from the region that is at proximity with dentate gyrus, CA3-CA2-CA1
(Amaral, D; Lavenex P;2006). The entorhinal cortex is typically the first region of the brain
that is susceptible to plaque deposition and tangle formation in AD.
The major neuronal connections to the hippocampus are through the entorhinal
cortex while its major output is through CA1. Neuronal projections in CA1 traverse via two
main pathways, that are termed as direct and indirect. The direct pathway involves axons
that originate from layer III in EC and form synapses with distal apical dendrites of CA1.
The indirect pathway involves axons originating from layer II of EC and finally to CA1
through the trisynaptic circuit. The initial part of this pathway involves axons from the
perforant pathway to the granule cells of the dentate gyrus (synapse 1). From there the
information follows through the mossy fibers to CA3 (synapse 2). CA3 axons
called Schaffer collaterals exit from the cell body and loop around the apical dendrites by
13

which they connect to CA1 (third synapse). Axons from CA1 then project back to the
entorhinal cortex, completing the circuit. In addition to the classical trisynaptic circuitry
where CA3 axons connect with CA1 axons, CA3 axons also form collaterals with other
CA3 neurons. This recurrent pathway lead to theories of CA3 as forming an autoassociative system of memory (Anderson et al.,2000).

Image not drawn to scale
Figure 7: Anatomy of hippocampus in mice.

1.09 Reelin signaling in the entorhinal-hippocampal formation
Neurons of the entorhinal cortex project to the hippocampus and are involved in
declarative memory formation and consolidation. Entorhinal cortex layer II neurons
provide the principal excitatory input to the dentate gyrus of the hippocampus. The
entorhinal cortex layer II neurons are one of the first neuronal populations to die in AD,
resulting in a severe loss of synaptic contacts to the dentate gyrus. Many of the entorhinal
cortex layer II neurons express Reelin and these Reelin-expressing cells are significantly
reduced in the brains of human amyloid precursor protein (hAPP) transgenic mice
expressing the Swedish and Indiana mutant form of the hAPP gene (hAPPsweind orJ20
strain). In accordance with the loss of these Reelin-expressing cells, Reelin levels in the
14

hippocampus of J20 mice are also significantly reduced (Chin et al., 2007). Similar loss of
Reelin-expressing entorhinal cortex layer II neurons is also observed in the brains of
patients with AD (Chin et al., 2007; Herring, 2012). Finally, in a transgenic rat model of AD
(McGill-R-Thy1-APP strain), Reelin-expressing neurons of the entorhinal cortex layer II
were found to selectively express increased levels of soluble intracellular A early in
disease, prior to the deposition of amyloid plaques (Kobro-Flatmoen, 2016). Collectively,
these studies suggest that loss of Reelin-expressing cells and their synaptic projections
to the hippocampus play a central role in the early pathogenic changes in AD (Krstic et
al., 2013). Moreover, deficiencies in Reelin signaling to the hippocampus likely underlie
some of the cognitive deficits observed in patients with AD (Cuchillo-Ibañez et al., 2016;
Yu et al., 2016). Therefore, strategies focused on rescuing the deficit in Reelin expression
and/or signaling might provide a novel therapeutic approach to treating AD.
1.10 Modulation of Reelin expression in AD alteration
As noted above, Reelin-expressing cells of the entorhinal cortex layer II are
significantly reduced in the hAPPSweInd (J20) transgenic mouse model of AD, coinciding
with a reduction in Reelin levels in the hippocampus of these mice. Further reducing Reelin
in these mice by crossing J20 mice with heterozygous reeler mice accelerates amyloid
plaque formation and tau pathology (Kocherhans, 2010). Conversely, Reelin overexpression in J20 AD model mice significantly delays amyloid plaque formation and
rescues cognitive deficits in these mice (Pujadas, 2014). Thus, J20 mice are an
established model of familial AD and the disease course of these mice is significantly
impacted by alterations in Reelin, making this an excellent model system to investigate
the potential therapeutic benefits of modulating Reelin expression.
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1.11 Oxidative stress
Oxidative species are free radical molecules that can arise from exogeneous or
endogenous sources (Kim, G. H. et al., 2015). Some of the exogeneous sources are UV
radiation, ionizing agents or drugs that have a non-specific mode of action mediated
through reactive oxygen species (ROS) production (Mani S. 2015). Endogenous sources
of ROS originate from reactions that occur in mitochondria or other non-mitochondrial
compartments which are natural by-products of metabolic processes. Some of the
enzymes that produce free radicals include nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (Nox), xanthine oxidase (XO), nitric oxide synthase (NOS), cytochrome
P450 from endoplasmic reticulum (ER), and flavin oxidases from peroxisomes (Song P et
al., 2015). Another source of ROS is through cytokine release from cellular death and
tissue injury. Immune neutralization reaction is also involved with a release of oxidative
species; reactions such as Antigen Presenting Cells (APC) that are targeted by immune
cells. Mitochondrial fission and autophagy are internally programmed mechanism that are
activated by cellular sensors from factors such as nutritional starvation or signaling cues
that also contribute to oxidative stress.
An excessive production of oxidative species or dysfunction in cellular antioxidant
system leads to oxidative stress which has been linked to aging and neurodegenerative
diseases. Oxygen tends to form free radicals due to unpaired electrons in its valence shell.
Therefore, ROS are a group of derivatives from oxygen molecules (Held P. 2012)
Superoxide radicals (O2•−), hydrogen peroxide (H2O2), hydroxyl radicals (•OH), and
singlet oxygen (1O2) are some of the examples of oxidative species. Oxygen radicals are
typically short-lived and highly reactive. Hence, they maybe transformed into a stable form
such as H2O2 by superoxide dismutase or be protonated to form HO2-. H2O2can further
decompose to form H2O and O2 via catalase or peroxidases. Hydroxyl ions are one of the
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most reactive species that have cytotoxic effects on cellular components. Hydroxyl ions
are also formed from H2O2 and O2 that is catalyzed by Fe ions which are known as
Fenton’s reaction (Zorov D.B, 2014).
There are physiological benefits of ROS when maintained at low to moderate
levels in the cell. Processes such as protein phosphorylation, migration, mitosis,
differentiation, immune activation takes place under ROS sensor system. To combat a
higher threshold of toxic oxidative species, cells deploy an antioxidant defensive system
that are composed of enzymatic components, such as superoxide dismutase (SOD),
catalase (CAT), and glutathione peroxidase (GPx) which uses glutathione (GSH) to
detoxify peroxides (Kim G.H., 2015). However, in an aged individual, these antioxidant
pathways are overwhelmed by ROS.
1.12 Immunocal®: GSH precursor and modulator of Reelin expression
Immunocal® is a non-denatured whey protein isolate and a rich source of the
glutathione (GSH) precursor cysteine. Supplements that only contain cysteine are not
viable source of glutathione since it is spontaneously catabolized by gastrointestinal tract
and blood. However, Immunocal® is metabolized in the liver to form cystine which is
resistant to trypsin proteolysis and can pass through the bloodstream. Cystine is
transported into neurons via the system xc− antiporter (Sxc−). Cystine is hydrolyzed to
form two cysteine molecules, which are then utilized in the de novo synthesis of GSH by γglutamylcysteine ligase (γ-GCL) and glutathione synthase (GSS) (Winter et al. 2017).
Glutathione is a tri-peptide (glutamate, cysteine, glycine) endogenous antioxidant.
Cysteine and glutamate in presence of enzyme γ-glutamyl synthetase (γ-GCS) forms γglutamylcysteine. Glutathione (GSH) is then synthesized from glycine and γglutamylcysteine in presence of glutathione synthetase (GS). GSH is further oxidized by
neutralizing various free radicals that are produced within the cell. Through kinetic studies,
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it has been observed that cysteine is the rate limiting substrate in the synthesis of
glutathione. Therefore, Immunocal® may be a potential source to increase cysteine that
could lead to a higher conversation rate to glutathione restoring cellular repair from
oxidative stress.
The ratio of reduced to oxidised glutathione (GSH:GSSG) within cells is used as
a marker of cellular toxicity. Under normal conditions, this ratio is known to be present in
mammalian cells in the concentration range of 1–10 mM. However, in a resting cell, the
molar GSH:GSSG ratio is found to be greater than 100:1, and in various models of
oxidative stress, this ratio has been observed to decrease considerably (Zitka, O. et al.
2012).
Immunocal® has been shown to boost levels of this essential antioxidant and
improve muscle strength in certain patient populations, healthy human volunteers, and
non-frail elderly subjects (Bounous et al. 1991; Grey et al. 2003). It was previously shown
that incubation with Immunocal® protects primary cerebellar granule neurons and various
neuronal cell lines from multiple stressors including glutamate, nitric oxide, and A (Winter
et al., 2017). Moreover, the neuroprotective effects of Immunocal® observed in vitro are
dependent on the de novo synthesis of GSH. In a similar manner, it was also shown that
oral treatment of G93A mutant hSOD1 transgenic mice with Immunocal® preserves spinal
cord GSH and delays disease onset in a mouse model of amyotrophic lateral sclerosis
(Ross et al. 2014). Finally, in a schizophrenia mouse model characterized by low brain
GSH and low Reelin levels, Immunocal® was recently shown to elevate both GSH and
Reelin in the brain (Song et al. 2017). In preliminary studies in the Linseman lab,
Immunocal® induces Reelin expression in vitro in hippocampal-entorhinal cortex
organotypic slices and rescues Reelin expression in vivo in J20 AD model mice at 5-
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months of age. Thus, Immunocal® has the capacity to increase brain GSH and in parallel,
enhance Reelin expression in both slice culture and mouse models.
Hypothesis: We hypothesize that oral treatment with the cysteine-rich whey protein
supplement, Immunocal®, from 3-month-old to 12-month-old will significantly rescue GSH
levels and Reelin expression in the entorhinal cortex-hippocampus of hAPPsweind mice as
well as ameliorate amyloid plaque neuropathology in this mouse model of AD.
1.13 Summary of Major Findings
We evaluated the effects of Immunocal® treatment in vivo by treating hemizygous
J20 hAPPsweind AD mice from 3 months-old to 12 months-old. We assessed Reelin
expression by western blotting and immunofluorescence microscopy. Immunocal®
treatment corrected a deficit in cortical GSH levels observed in the brains of untreated
hemizygous J20 mice. Western blotting of brain sections micro-dissected to enrich for the
hippocampal-entorhinal cortex sub-region revealed a decrease in Reelin expression in
untreated hemizygous J20 AD mice compared to non-carrier control mice. These deficits
were corrected by treatment with Immunocal®. In a similar manner, using
immunofluorescence microscopy, Reelin expression was diminished in the entorhinal
cortex, dentate gyrus and CA1/CA3 regions of the hippocampus in untreated hemizygous
J20 AD mice compared to non-carrier control mice. In contrast, Immunocal® treatment
rescued these deficits in Reelin expression. Since reelin protein is ubiquitously produced
in all regions of the brain, we analyzed reelin transcripts in hippocampal region of J20 AD
mice by in situ hybridization. We found that reelin mRNA levels were significantly reduced
in entorhinal cortex region of hippocampus and this deficit was also rescued by treatment
with Immunocal®. In parallel with the observed rescue of Reelin expression in the
hippocampus-entorhinal cortex of J20 mice, Immunocal® also preserved GAD67
expression in the dentate gyrus and CA3 region of the hippocampus. Perhaps most
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importantly in the context of AD, we evaluated the deposition of amyloid plaques in the
J20 mice. These mice have been shown to have significant plaque load at 12-months-old.
We show that untreated J20 mice do indeed accumulate a significant plaque load in the
hippocampus and entorhinal cortex. After treatment with Immunocal® the plaque load was
diminished quite dramatically, both in size and number.
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Chapter Two: Materials and Methods
2.01 Reagents
Immunocal® was provided by Immunotech (Vaudreuil-Dorion, QC, CA). Gey’s
balanced salt solution and ProLong Gold was purchased from Invitrogen (Carlsbad, CA,
US). Primary antibodies for Reelin (ab78540), NeuN (ab104225), DRAQ7™, and β-actin
(ab 115777) were purchased from Abcam (Cambridge, UK). Secondary antibodies for
immunofluorescence were purchased from Jackson Immunoreserach (Westgrove, PA,
US). Horseradish peroxidase (HRP) secondary antibodies for Western blotting were
purchased from Bio-Rad, catalogue no. 1706515 (Hercules, CA, US). All probes
(RNAscope® Probe Mm-Reln-C3 catalogue no. 319361-C3) and reagents (RNAscope®
fluorescent multiplex kit, catalogue no.320850) for in situ hybridization were purchased
from Advanced Cell Diagnostics (Newark, CA, US). Amylo-Glo was purchased from
Biosensis (Thebarton, SA, AU).
2.02 Experimental model:
To investigate the effects of Immunocal® on Reelin expression in vivo, we utilized
the hAPP(Swe/Ind) mutant transgenic mouse model of AD (J20 strain). This mouse model
is commercially available from Jackson Laboratories (B6.Cg-Tg(PDGFB-APPSwInd)
20Lms/2Mmjax) and displays significant brain pathology, amyloid plaques, and cognitive
deficits that recapitulates multiple aspects of AD in humans (Mucke et al., 2000; Karl et
al., 2012; Diaz-Hernandez et al., 2012). According to previous reports, these transgenic
mice typically show significant cognitive deficits, diminished numbers of Reelin-positive,
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entorhinal cortex (EC) layer II neurons, and decreased Reelin expression in the
hippocampus by approximately 4-5 months of age. Above, in concordance with the
literature, we demonstrated that these mice show deficits in GSH, elevated oxidative
stress, and reduced levels of Reelin protein in the hippocampal-entorhinal cortex formation
at 5-months of age. As these mice age, amyloid plaques (a hallmark of AD pathology) are
visible in the brains of these mice by around 12-months of age. All animal studies were
conducted in accordance with a protocol approved by the University of Denver Institutional
Animal Care and Use Committee.
2.03 Immunocal® treatment:
To address this experimental question required three groups of mice:
hAPP(Swe/Ind) mutant hemizygous mice (J20 strain) treated with Immunocal® (3.3% w/v
in drinking water ad libitum, as previously described by Ross et al., 2014), untreated
hemizygous J20 mice, and untreated non-transgenic (non-carrier) control mice.
Immunocal® treatment was initiated at 3-months-old and continued until the mice were
12-months-old.
2.04 Analysis of brain GSH and GSSG by HPLC with electrochemical detection
(HPLC-ECD)
2.041 Tissue processing:
Cortical tissue was obtained from mice and immediately frozen in liquid nitrogen.
For HPLC-ECD analysis, 2.5M perchloric acid was added and the brains were roughly
chopped using pointed surgical scissors. Samples were then sonicated 3 times for 15s
intervals. Samples were then centrifuged for 5min at 13,000rpm and the supernatant was
removed. A 20µL aliquot of the supernatant was used for a BCA protein assay. The
remainder of each solution was neutralized with 500µL of 4M KOH and vortexed
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thoroughly. Samples were then centrifuged for 15min at 13,000rpm, and stored at -80°C
until separation and analysis by HPLC-ECD.
2.042 HPLC-ECD:
GSH in samples and known standards were separated by reversed-phase HPLC
on a C18 bonded silica column at 35°C (5µm, 4.6mm x 25cm) from Tosoh Bioscience.
(Grove City, OH, US). Analytes were detected using a CoulArray® detector (model 5600,
ESA) on three coulometric array cells in series; electrochemical detectors were set
between 0 and 900mV at increments of 75mV. Concentrations were determined with a
standard curve of each identified analyte. Mobile phase consisted of 50mM lithium acetate
and 1% acetonitrile in water, pH 3.8. The flow rate was set to 0.4mL/min for all samples.
CoulArray® software was used for baseline correction and peak analysis.
2.05 Western Blotting
Mice brain was rapidly dissected where one hemisphere was placed into ice cold
Gey’s balanced salt solution for slicing while the other half was flash frozen in liquid
nitrogen and stored at -800C. Briefly, the flash frozen half were thawed, then brain slices
were lysed using a Dounce homogenizer and Wahl lysis buffer supplemented with
aprotinin and leupeptin. The samples were diluted 1:100 for a BCA protein assay. Western
immunoblotting was done to immunochemically detect proteins immobilized on
polyvinylidene difluoride (PVDF) membranes. Protein samples (50 µg/lane) were resolved
by SDS-PAGE and proteins were then transferred to PVDF membranes. Non-specific
binding sites were blocked using 1% BSA in PBS (pH 7.4) containing 0.1% Tween-20
(PBS-T) for 1 h at 25°C. The blocking buffer was drained, and the membrane was allowed
to incubate in primary Reelin antibody (1:1000) diluted in blocking buffer overnight at 4 °C.
The membrane was washed 3 times for 15min in PBS-T. Immunoreactive proteins were
detected using enhanced chemiluminescence (GE Healthcare; Pittsburgh, PA) and films
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were developed using a ChemiDoc developer (BioRad, Hercules, CA). Re-probing of blots
was performed by stripping in 0.1 M Tris-HCl (pH 8.0), 2% SDS, and 100 mM βmercaptoethanol for 30min at 52 °C. The blots were rinsed twice in PBS-T and processed
as above with a different primary antibody. Relative intensities of the protein bands were
quantified by scanning densitometry using ImageJ.
2.06 Insitu mRNA Hybridization
Samples were processed according to ACD RNAscope Fluorescent Multiplex
Assay manual (Newark, CA, US). Using a vibratome (Leica), brain tissue was freshly
sliced in ice cold Gey’s balanced salt solution at (roughly 500 µM thickness) such that the
hippocampal entorhinal cortex region was preserved, then the slices were embedded in
OCT and frozen in liquid nitrogen. Brains were then sliced at 30µm thickness with a
cryostat (Leica CM 1950) and adhered onto SuperFrost Plus Slides and stored at -800C
until use. Sliced tissues were permeabilized using 4% paraformaldehyde (PFA) and
incubated for 15min. Slides were rinsed twice with 1X PBS (pH 7.4) buffer. Tissues were
dehydrated consecutively in 50%, 70% and 100% ethanol for 2min each. A barrier was
created around the tissue using a hydrophobic pen. Tissues were then incubated in
protease inhibitor for 30min at 25°C in HybEZ™ Humidity Control Tray. About 4-6 drops
of Reelin or NeuN (positive control) probe was added to tissues. The slides were inserted
in slide holder and placed in HybEZ™ Humidity Control Tray and incubated for 2h at 400C
in HybEZ™ Oven. After washing in 1X PBS buffer, samples were hybridized by adding 46 drops with Amp1, Amp2 and Amp3 for 30, 15, 30min respectively at 400C. Samples were
incubated with FITC dye for 15min at 25°C and counter stain DRAQ™ was added for
15min.

24

2.07 Immunofluorescence
Using a vibratome (Leica), brain tissue was freshly sliced in ice cold Gey’s
balanced salt solution at (200µM thickness) such that the hippocampal entorhinal cortex
region was preserved, then was added to a 6-well plate (1 slice/well) containing ice cold
4% PFA and fixed for 90min. Fixative was removed from the wells and the slices were
washed three times for 5min in PBS-T. After the final wash, PBS-T was removed and 1ml
of Blocking Solution (5% BSA, 1× PBS, 0.05% Tween-20, pH 7.4) was added to the wells
and incubated at 25°C for 90min. Blocking solution was replaced with primary antibody in
blocking solution at the specified dilutions. (Table 1) and incubated overnight at 40C. The
following day, primary antibody was removed, and the tissue was washed 3 times for 5min
in PBS-T. Slices were then incubated with the secondary antibody diluted in blocking
solution at the indicated concentrations for 90min at 25°C. Then, secondary antibody
solution was removed and immediately replaced with 1ml of DRAQ7™ diluted in PBS-T
and incubated for 20min at 25°C. The tissue was carefully transferred to a glass slide
SuperFrost Plus Slide and excess PBS-T was removed using a Kimwipe Prolong Gold
was added onto the tissue and coverslip was placed over it.
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Table 1: Antibody concentration and stains

Primary Antibody
Reelin (RELN)
GAD67
NeuN

Secondary antibody
Fluorescein
Isothiocyanate (FITC)
conjugated
Cyanine-3 (Cy3)
conjugated
HRP conjugated
Stains
DRAQ7™
Amylo-Glo®

Host
Monoclonal mouse anti
reelin
Monoclonal mouse anti
GAD67
Rabbit polyclonal anti
NeunN

Dilution
1:1000

Host
anti-goat/rabbit/mouse
depending on the
primary
anti-goat/rabbit/mouse
depending on the
primary
Goat anti-mouse HRP

Dilution
1:5000

Nuclear specific stain
Aβ plaque specific stain

1:1000
1:100

1:1000
1:1000

1:5000

1:5000

2.08 Quantification of reelin staining and amyloid plaques
Images were collected using Olympus FLUOVIEW FV3000 confocal laser
scanning microscopy using an Olympus 20X PLN objective. Confocal z-series were
captured at same exposure times across all samples (n=4 to 5 in each group for protein
staining and n=3 in in situ hybridization). Each region of hippocampus (EC, DG, CA3/CA1)
was captured in triplicates. Total fluorescent intensity was analyzed in Adobe Photoshop
for protein staining and in situ hybridization. Any adjustments made in the analysis step
was accounted constant for all the groups.
For amyloid quantification by image J software, the color images were converted
in to HSV format and 8-bit channels. Plaques were quantified in an unbiased manner by
an investigator blind to the treatment nature of the samples. Plaque number was
calculated from each area of hippocampus whereas plaque load was calculated as the
area occupied by the plaques divided by the total brain region area.
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2.09 Statistical analysis
All the data collected were analyzed with GraphPad Prism 5 software using oneway analysis of variance (ANOVA) followed by a post-hoc Tukey’s test. Descriptive
statistics were displayed as an expressed mean ± S.E.M. Quantitative differences were
deemed significant when p < 0.05.
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Chapter Three: Results
3.01 Glutathione Analysis
We measured the brain levels of reduced glutathione (GSH) and oxidized
glutathione disulfide (GSSG) in cortical tissue from the mice using HPLC-ECD. Untreated
hemizygous J20 mice displayed a reduction in cortical GSH and a dramatic increase in
GSSG at 12-months-old when compared to non-carrier control mice (Fig. 8 A, B).
Hemizygous J20 mice treated with Immunocal® showed a complete preservation of
cortical GSH and a reduction in GSSG, both of which were statistically significantly
different from the levels observed in untreated hemizygous mice (Fig. 8 A, B).
Furthermore, the GSH/GSSG ratio, a key measure of oxidative stress, showed a
statistically significant reduction in the untreated hemizygous mice when compared to the
non-carrier control mice (Fig. 8 C). This indicates increased oxidative stress in the brain
of J20 AD mice. This effect was completely prevented by treatment with Immunocal® from
3-months-old to 12-months-old (Fig. 8C). Therefore, Immunocal® treatment corrects a
deficit in brain GSH, reduces levels of GSSG, and diminishes the abnormal levels of
oxidative stress as indicated by the GSH to GSSG ratio observed in AD model mice.
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Analysis of Reelin Transcript levels

Fig. 8. Immunocal® treatment preserves brain GSH in J20 AD model mice. Brain (cortical) tissue was harvested
from 12-month-old hemizygous J20 AD mice (either untreated (Unt) or treated with Immunocal® (ICAL) for 2 months
and non-carrier control mice. Tissue was extracted and reduced GSH and glutathione disulfide (GSSG) were measured
by HPLC with electrochemical detection. Values are normalized to protein content represented as mean±SEM for n=3
mice per group. Statistical differences were calculated by one-way ANOVA with a post hoc Tukey’s test. ns=not
significant, *p<0.05, **p<0.01, ***p<0.001.
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3.02 In situ mRNA Hybridization for reelin transcript
We used in situ hybridization technique to analyze regions of hippocampus that
express reelin transcripts. Entorhinal cortex (EC) is a primary region in hippocampus to
produce reelin. Along with EC, interneurons also synthesize reelin in the CA3 region. In
this study, we found mRNA expression for reelin mostly concentrated in the regions of
hilus layer in dentate gyrus, CA3 and entorhinal cortex of hippocampus. We compared
regions of entorhinal cortex and CA3 of non-carrier with hemizygous untreated and
Immunocal® J20 mice. There was a significant decrease in reelin transcript levels
detected in CA3 and EC regions of hemizygous untreated mice when compared to noncarrier. Immunocal® treatment significantly preserved reelin transcript expression only in
the EC (Fig. 9 A,B).
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Fig. 9. Immunocal® treatment increases Reelin mRNA expression in hippocampal-entorhinal
cortex slices. (A) Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice
(either untreated (Unt) or treated with Immunocal® (ICAL) for 9 months) and non-carrier control
mice. Formalin-fixed sections were hybridized with anti-sense Reelin transcript (Rln, shown in
green) along with Draq (nuclear stain, shown in blue). Scale bar = 250µm
(B) The graph indicates total fluorescent intensities for (n = 3) mice in CA3 and EC region of
hippocampus. Reelin was significantly decreased in CA3 and EC in untreated hemizygous mice
compared to non-transgenic controls. ICAL treatment significantly preserved Reelin staining in the
hemizygous mice only in EC. Statistical differences were calculated by one-way ANOVA with a post
hoc Tukey’s test.
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3.03 Analysis of Reelin Expression – Western Blotting
We next evaluated the expression of Reelin protein in the 12-month-old J20 AD
mice by western blotting brain tissues enriched for the hippocampal-entorhinal cortex
formation. Reelin expression was significantly reduced in untreated hemizygous J20 AD
mice compared to non-carrier controls and Immunocal® treatment largely corrected this
deficiency (Fig. 10A). The Reelin blots were stripped and re-probed for beta-actin as a
loading control. We detected the 180 kDa cleavage fragment of Reelin in these mouse
brain lysates. Quantitative densitometric analysis of the 180 kDa Reelin band (normalized
to β-actin) revealed an approximate 30% reduction in Reelin protein expression in
hemizygous untreated AD mice compared to non-carrier controls, and a complete
preservation of Reelin expression in Immunocal®-treated mice (Fig. 10B). In concordance
with the literature, we show a reduction in the Reelin protein levels by western blot in 12month-old J20 AD mice. We also show that treatment with Immunocal® rescues this
Reelin deficit in the hippocampal-entorhinal cortex formation
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Fig 10. Immunocal® treatment rescues Reelin expression by western blotting in J20 AD model mice. Brain
tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice (either untreated (Unt) or treated with
Immunocal® (ICAL) for 9 months) and non-carrier control mice. Tissue was micro-dissected to enrich for the
hippocampal-entorhinal cortex sub-region. (A) Brain lysates were resolved by SDS-PAGE and immunoblotted for
Reelin. The Reelin blot was stripped and re-probed for beta-actin. (B) The graph shows the densitometric analysis of
the 180 kDa Reelin bands normalized to the beta-actin bands in arbitrary units (n=3 mice per group). Statistical
differences were calculated by one-way ANOVA with a post hoc Tukey’s test. *p<0.05.

3.04 Analysis of Reelin Expression – IHC
We then used IHC and immunofluorescence microscopy technique to evaluate
eelin expression in the entorhinal cortex, dentate gyrus, and CA1/CA3 regions of the
hippocampus in 12-month-old J20 AD model mice. In comparison to the non-carrier
control, untreated hemizygous J20 AD mice displayed a significant reduction in Reelin
immunoreactivity in all the regions of hippocampus. Intriguingly, treatment with
Immunocal® from 3 months-old to 12 months-old largely rescued this deficit in Reelin
expression within dentate gyrus and entorhinal cortex region of J20 AD mice (Fig. 11 AD).
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Fig 11. Immunocal® treatment rescues Reelin expression by Immunohistochemistry in J20 AD model
mice. Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice (either untreated (Unt) or
treated with Immunocal® (ICAL) for 9 months) and non-carrier control mice. Formalin-fixed sections were costained with antibodies to Reelin (Rln, shown in green) and NeuN (shown in red), along with Draq (nuclear stain,
shown in blue). Scale bar = 250µm
The graph indicates total fluorescent intensities for (n = 4-5) mice in each region of the hippocampus. Reelin
was significantly decreased in (A)EC, (B)DG, (C)CA1, and (D)CA3 in untreated hemizygous mice compared to
non-transgenic controls. In the EC and DG, ICAL treatment significantly preserved Reelin staining in the
hemizygous mice. Statistical differences were calculated by one-way ANOVA with a post hoc Tukey’s test.
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3.05 Analysis of Amyloid plaque load
The J20 mice have been shown to have extensive amyloid-beta plaque loads in
the hippocampal entorhinal cortex formation by 12-months of age. To evaluate the effects
of Immunocal® treatment on the deposition of amyloid plaques we used Amylo-glo, an
amyloid peptide aggregate-specific stain used to mark amyloid plaques. After treating the
mice from 3-months-old to 12-months-old with Immunocal® there was a dramatic
reduction in the amyloid plaque load in the hippocampal entorhinal cortex formation of the
J20 mice (Fig. 12). In the dentate gyrus, CA3 and CA1 hippocampal regions of untreated
J20 mice there was a significant plaque load throughout with distinct dense formations
(Fig. 12). After treatment with Immunocal® for 9-months, this plaque load was greatly
diminished in the hippocampus and the plaques that are visible are much smaller in
diameter and density (Fig. 12). When we evaluated the entorhinal cortex of untreated J20
mice we show a similar number of plaques, however a reduced size and density of
amyloid-beta plaques relative to the hippocampus. The Immunocal® treated mice have
diminished size and density of amyloid plaques in the entorhinal cortex (Fig. 12). We
quantified the total plaque number and total plaque load (plaques/area) and show
significant reductions in all areas of the hippocampus and entorhinal cortex, with the
exceptions of CA3 which shows a trend towards significance (Fig. 13 A, B). These data
show the ability of Immunocal® treatment to suppress and delay the formation of amyloid
plaques in the hippocampus and entorhinal cortex of the J20 mouse model of AD.
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Fig 12. Immunocal® treatment reduces amyloid-beta plaque load in the hippocampal-entorhinal
cortex of J20 AD model mice. Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20
AD mice (either untreated (Unt) or treated with Immunocal® (ICAL) for 9 months). Formalin-fixed sections
were co-stained with Amylo-glo (amyloid peptide aggregates) in green along with Draq (nuclear stain,
shown in grey scale) Scale = 500µm
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Fig 13. Quantification of amyloid plaque number and plaque load (A) amyloid
plaque load (number of plaques/area) (B) for distinct regions of the hippocampus
(dentate gyrus, CA3, CA1) and entorhinal cortex. Data expressed as meanSEM, dots
are individual subject means (n=4). *p<0.05, **p<0.01.
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Chapter Four: Discussion
Reelin is a secretory glycoprotein that plays a role in the maintenance and
regulation of LTP in neuronal synapses. Its sets a foundation for neuronal cells to be
placed in right areas of the brain and continues to play a role in brain development through
the lifetime of an individual. Therefore, its deficit can lead to severe debilitation of motor
functions that finally affect involuntary activity. Addressing all the functions of reelin,
especially those that are imperative in consolidation of neural network, we used cysteinerich whey protein, Immunocal® for a fixed amount of time period and checked for
resurgence/rescue of reelin in AD mouse model. Previous studies showed that
Immunocal® elevate glutathione in the brain and spinal cord which acts as a
neuroprotective agent from oxidative stress. This potential nutraceutical has been tested
as a therapeutic source for schizophrenia and ALS mouse model (Ross et al., 2014; Song
et al., 2017). From this study it was shown that, Immunocal® rescued reelin at the
transcript and protein level in the prefrontal cortex of mouse model of schizophrenia.
However, in AD patients, it is known that neuronal population of reelin secretory cells of
Entorhinal cortex is most vulnerable to neurodegeneration. Therefore, we designed the
experiment to first observe the site of synthesis in hippocampal region of mouse brains in
the wild type and AD model. Consequently, we sought to evaluate the effects of
Immunocal® on Reelin expression and signaling in vitro in hippocampal-entorhinal cortex
rat brain slices and in vivo in the hAPPSweInd mutant (J20) mouse model of AD. Previous
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work has shown that deficits in Reelin expression and/or Reelin signaling play a
pathogenic role in several nervous system disorders including schizophrenia and AD.
Thus, strategies aimed at correcting these deficits might provide a novel therapeutic
approach to these devastating diseases. The cysteine-rich, whey protein supplement,
Immunocal®, has previously been shown to elevate glutathione in the brain and spinal
cord and is neuroprotective and therapeutically efficacious in mouse models of
schizophrenia and amyotrophic lateral sclerosis (Ross et al., 2014; Song et al., 2017).
Most recently, Immunocal® treatment has been shown to rescue Reelin expression at the
mRNA and protein level in the prefrontal cortex of a mouse model of schizophrenia (Song
et al., 2017). Given that Reelin expressing neurons of the entorhinal cortex layer II are a
highly vulnerable population of cells that are lost very early in AD, we sought to evaluate
the effects of Immunocal® on Reelin expression and signaling in vitro in hippocampalentorhinal cortex rat brain slices and in vivo in the hAPPSweInd mutant (J20) mouse model
of AD.
We evaluated the effects of Immunocal® treatment in vivo by treating hemizygous
J20 AD mice from 3 months-old to 12 months-old. We assessed Reelin expression and
signaling by western blotting and immunofluorescence microscopy. Immunocal®
treatment corrected a deficit in cortical GSH levels observed in the brains of untreated
hemizygous J20 mice. Western blotting of brain sections micro-dissected to enrich for the
hippocampal-entorhinal cortex sub-region revealed a decrease in Reelin expression in
untreated hemizygous J20 AD mice compared to non-carrier control mice. These deficits
were corrected by treatment with Immunocal®. We evaluated Reelin transcript levels in
hippocampal region of brain by in situ hybridization and quantified transcript levels by
measuring total fluorescence intensity.
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In order to probe for hippocampal specific regions of reelin expression, we used
immunofluorescence microscopy technique. Reelin expression was diminished in the
entorhinal cortex, dentate gyrus and CA1/CA3 regions of the hippocampus in untreated
hemizygous J20 AD mice compared to non-carrier control mice. In contrast, Immunocal®
treatment largely rescued these deficits in Reelin expression and in entorhinal cortex and
dentate gyrus significantly. Since reelin is a secreted glycoprotein, it was observed to be
present in all regions of hippocampus as seen in non-carrier mice. Therefore, we used
insitu mRNA hybridization technique to investigate specific regions of hippocampus that
synthesize reelin transcripts. Entorhinal cortex, CA3 and dentate gyrus of hippocampus
were the only regions that expressed reelin transcripts. Due to tissue integrity being lost
during slicing procedure in dentate gyrus, we assessed transcript levels only in CA3 and
entorhinal cortex. There was a significant reduction in transcript expression in
heterozygous untreated sample when compared with non-carrier. However, there was a
significant rescue in mRNA levels in entorhinal region of Immunocal® treated sample. We
suspect that entorhinal region may be involved in production of reelin through which other
regions of hippocampal receive signal from trisynaptic pathway that is involved in long
term potentiation.
Perhaps most importantly in the context of AD, we evaluated the deposition of
amyloid plaques in the J20 mice. These mice have been shown to have significant plaque
load at 12-month-old. We have shown that untreated J20 mice do indeed accumulate a
significant plaque load in the hippocampus and entorhinal cortex. After treatment with
Immunocal® the plaque load was diminished quite dramatically, both in size and number.
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Chapter Five: Future direction and potential mechanism
The mice model used in this study only forms one of the pathological characteristics
of Alzheimer’s disease that is, Aβ plaques. In order to capitulate complete disease state,
it would be interesting to use a mice model that also forms tangle pathology such as those
seen in 3XTg-AD. Using this model may provide cues to reelin downstream signaling
pathway. We would also like to probe for inflammatory response which could serve as an
indicative of oxidative stress and cell injury in J20 as well as 3XTg-AD model by staining
for microglial and astrocyte markers.
Based on these preliminary results, we have postulated a mechanism that may work
towards reduction of pathological characteristics in AD. If Immunocal® treatment is
initiated early-on, it increases glutathione levels in neuronal cells which decreases the
excessive reactive oxidative species (ROS) generated through aging process. In a
preliminary study from our lab, Immunocal® treatment was tested from 3-month old to 5month old mice. In one of the experiments, we used transcription regulator p-CREB to test
modulation of reelin synthesis. This transcriptional element is found upstream of reelin
gene and maybe repressed under oxidative stress condition. We performed western
blotting to observe p-CREB levels in control, untreated hemizygous J20 mice model and
treated J20 mice model. The untreated hemizygous J20 AD mice displayed a marked
reduction in p-CREB immunoreactivity in the hippocampal-entorhinal cortex sub-region of
the brain and this deficit was essentially rescued by treatment with Immunocal®. With this
we postulate that p-CREB maybe involved in activation of reelin levels in the cell.
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Therefore, reelin levels increase in response to an increase in glutathione levels. As
documented in this study, augmentation of reelin can decrease pathological effects in AD
such as Aβ plaques and tau fibrils.

Figure 14: Potential mechanism of Immunocal® as a therapeutic in AD
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Appendix: Abbreviations
AD: Alzheimer’s disease
AKT: Protein kinase B also known as AKT
APC: Antigen presenting Cell
ApoER2: Apolipoprotein E receptor-2
APP: Amyloid precursor protein
hAPP: human Amyloid precursor protein
ANOVA: Analysis of variance
BACE: β secretase
BCA: Bicinchoninic acid assay
BSA: Bovine serum albumin
CDC: cell cycle division
CA: Cornus Ammonis
CAT: catalase
CR: Cajal Retzius
Ct: C-terminal
Cy3: Cyanine-3 conjugated
DAB1: Disabled-1
DG: Dentate gyrus
EC: Entorhinal cortex
ER: Endoplasmic reticulum
FITC: Fluorescein Isothiocyanate conjugated
Fyn: Proto-oncogene tyrosine-protein kinase fyn
GABA: gamma-aminobutyric acid
γ -GCS: γ-glutamyl synthetase
GAD: Glutamate decarboxylase
GS: Glutathione synthetase
GPx: Glutathione peroxidase
GSH: Glutathione
GSSG: Glutathione disulphide
HPLC-ECD: High performance liquid chromatography and electro-chemical detection
HRP: Horseshoe radish peroxide
HSV: Hue, saturation, lightness
KOH: Potassium hydroxide
LTP: Long term potentiation
PAK: Serine/threonine-protein kinase
PBS: Phosphate buffered solution
PFA: Para formaldehyde
PI3k: Phosphoinositide 3-kinase
PS1: presenilin 1
PS2: presenilin 2
PVDF: Polyvinylidene difluoride
NADPH: Nicotinamide adenine dinucleotide phosphate
Nox: NADPH oxidase
NOS : Nitric oxide synthase
NMDA: N-methyl-D-aspartate receptor
Nt: N-terminal
ROS: Reactive Oxygen Species
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R: Repeats
SDS-PAGE: Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis
S.E.M. : Standard error of the mean
SOD: Superoxide dismutase
Src: Proto-oncogene tyrosine-protein kinase src
SweInd: Swedish Indiana mutant
VLDLR: very low density lipoprotein receptor
XO: xanthine oxidase
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